1. �½�ά�������������ҽԺ
2. �½�ά�������������ҽԺƤ���Բ���

��ժҪ�� ���Ժ�������һ�ֶ��Զȸߡ�ת���硢��չ�졢Ԥ�������ʸߵ��ص��Ƥ���������Դ�ͳ���Ʒ�������ƺͻ��ƾ�����������Ч�Ŀǰȱ�ٽ�Ϊ��Ч�����Ʒ��������Ժ�����Ϊ����Դ�Խϸߵ���������ˣ����Ժ����������������о��ѳ�Ϊ����廯�ۺ����Ƶ���Ҫ��ɲ��ּ��о��ȵ㡣�������������Ǵ̼�������������ϵͳ���ֿ���֢�����Ʒ���������������ǿ����Ч�־úͲ�����ӦС���ŵ㡣Ŀǰͨ�����ߵ����Ե���¡�������ơ�ϸ���������ơ��������ƺ͹�����Tϸ�����Ƶȶ������Ʒ�ʽ����������Ӧ���ڶ��Ժ����������ƣ����������˶��Ժ��������ߵ�Ԥ��Ϊ�з����Ժ����������Ʒ����ṩ��˼·��

Zulihumaer��Mosha, Kang Xiaojing Graduate School of Xinjiang Medical University, Urumqi 830000, China ��Zulihumaer M��; Department of Dermatology and Venereology, People��s Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830001, China ��Kang XJ�� Corresponding author: Kang Xiaojing, Email: drkangxj666@163.com ��Abstract�� Malignant melanoma ��MM�� is a kind of highly malignant skin neoplasm characterized by early metastasis, rapid progression, poor prognosis and high mortality. It is insensitive to conventional therapies such as radiotherapy and chemotherapy. Effective therapeutic approaches are unavailable currently. MM shows high immunogenicity, thus immunotherapy for MM has become an important part of individualized comprehensive treatment and a research hotspot. Immunotherapy can stimulate the body��s immune system against cancer, and has advantages of strong specificity, lasting effects and less side effects. At present, various types of immunotherapy, such as immunoregulatory monoclonal antibody therapy, cytokine therapy, vaccine and adoptive T?cell immunotherapy, have been applied alone or in combination for the treatment of MM. They have significantly improved the prognosis of patients with MM and provided ideas for development of new therapies of MM.

�½�ά�����������Ȼ��ѧ����������Ŀ